Pregnancy can be a challenging journey, especially when compounded with health conditions like diabetes. A pioneering technology has emerged, promising a brighter, healthier future for pregnant women with diabetes. Let’s dive into what this means for mothers-to-be.
Researchers from the University of East Anglia have unveiled a groundbreaking technology known as the ‘hybrid closed-loop technology’ or, in simpler terms, the Artificial Pancreas. This technology administers insulin doses as guided by an algorithm on a smartphone. Yes, you heard that right—a smartphone!
The goal? To help pregnant women with type 1 diabetes achieve better control over their blood sugar levels compared to the traditional methods of insulin delivery.
Why This Matters
According to Prof Helen Murphy of UEA’s Norwich Medical School, hormonal changes and altered eating habits during pregnancy can make it incredibly challenging for women to maintain ideal blood sugar levels. The consequences are concerning. In fact, complications linked to type 1 diabetes during pregnancy impact one out of every two newborns. These complications can range from premature births to a lifelong risk of obesity for the baby.
On the maternal side, common challenges include low blood sugars, excessive weight gain, and high blood pressure during pregnancy. Hence, the drive to discover how automated insulin delivery could be the solution these women need.
How Does It Work?
Imagine a system that consistently fine-tunes insulin doses according to ever-changing blood sugar levels during pregnancy. This revolutionary technology does just that! It communicates with continuous glucose monitoring and insulin pump systems and adjusts insulin doses every 10-12 minutes.
A comprehensive study involving 124 pregnant women with type 1 diabetes, ranging from ages 18 to 45, was conducted. These women were split into two groups: one used the new Hybrid Closed-Loop technology, while the other stuck with traditional insulin therapy.
The study’s duration was approximately 24 weeks, spanning crucial months of pregnancy. Its scope was vast, with participation from nine NHS hospitals across England, Scotland, and Northern Ireland.
Stellar Results
A whopping 95% of the pregnant women utilised the Hybrid Closed-Loop technology consistently. Prof Murphy shared the promising outcomes: women who embraced this tech had blood sugar levels more in line with recommended targets—68% in the ideal range, compared to 56% with traditional methods. This improvement translates to an extra 2.5 to 3 hours in the target range daily throughout pregnancy.
Additionally, the technology proved its effectiveness across the board. Regardless of age, past blood sugar levels, or previous insulin therapy methods, the women experienced consistent benefits. Notably, these remarkable outcomes did not come with added risks of low blood glucose events or the need for more insulin.
There’s more good news: women using this technology gained approximately 7.7 lbs less and had fewer blood pressure complications. Plus, they required fewer appointments and made fewer emergency calls, hinting at a more efficient healthcare experience for both pregnant women and maternity services.
A Bright Future Ahead
Prof Murphy passionately remarks, “For a long time, there has been limited progress in improving blood sugars for women with type 1 diabetes.” This pioneering technology brings fresh hope. Consistent blood sugar levels during pregnancy can dramatically decrease risks for both the mother and baby.
However, it’s worth noting the study had certain limitations. A more extensive study is needed for an in-depth look at baby health outcomes. The current results are also specific to the CamAPS technology and might not apply to other systems not designed for pregnancy.